NASDAQ:ABEO - Access Pharmaceuticals Stock Price, Price Target & More

$20.00 -0.90 (-4.31 %)
(As of 04/23/2018 04:00 PM ET)
Previous Close$20.00
Today's Range$19.75 - $22.00
52-Week Range$4.55 - $22.75
Volume1.57 million shs
Average Volume1.12 million shs
Market Capitalization$987.04 million
P/E Ratio-30.30
Dividend YieldN/A
Beta1.29

About Access Pharmaceuticals (NASDAQ:ABEO)

Access Pharmaceuticals logoAbeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Receive ABEO News and Ratings via Email

Sign-up to receive the latest news and ratings for ABEO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ABEO
CUSIPN/A
Phone214-665-9495

Debt

Debt-to-Equity RatioN/A
Current Ratio25.10%
Quick Ratio25.11%

Price-To-Earnings

Trailing P/E Ratio-30.30
Forward P/E Ratio-25.32
P/E GrowthN/A

Sales & Book Value

Annual Sales$840,000.00
Price / Sales1,124.52
Cash FlowN/A
Price / CashN/A
Book Value$3.64 per share
Price / Book5.49

Profitability

EPS (Most Recent Fiscal Year)($0.66)
Net Income$-27,310,000.00
Net Margins-3,263.92%
Return on Equity-24.57%
Return on Assets-22.94%

Miscellaneous

Employees42
Outstanding Shares47,230,000

How to Become a New Pot Stock Millionaire

Access Pharmaceuticals (NASDAQ:ABEO) Frequently Asked Questions

What is Access Pharmaceuticals' stock symbol?

Access Pharmaceuticals trades on the NASDAQ under the ticker symbol "ABEO."

How were Access Pharmaceuticals' earnings last quarter?

Access Pharmaceuticals Inc. (NASDAQ:ABEO) released its quarterly earnings results on Friday, March, 16th. The biopharmaceutical company reported ($0.19) EPS for the quarter, missing the Zacks' consensus estimate of ($0.14) by $0.05. The biopharmaceutical company had revenue of $0.22 million for the quarter, compared to analyst estimates of $0.24 million. Access Pharmaceuticals had a negative return on equity of 24.57% and a negative net margin of 3,263.92%. The firm's quarterly revenue was down 16.0% compared to the same quarter last year. View Access Pharmaceuticals' Earnings History.

When is Access Pharmaceuticals' next earnings date?

Access Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, May, 21st 2018. View Earnings Estimates for Access Pharmaceuticals.

What price target have analysts set for ABEO?

8 brokerages have issued twelve-month price targets for Access Pharmaceuticals' shares. Their predictions range from $26.00 to $36.00. On average, they expect Access Pharmaceuticals' share price to reach $30.4286 in the next twelve months. View Analyst Ratings for Access Pharmaceuticals.

What are Wall Street analysts saying about Access Pharmaceuticals stock?

Here are some recent quotes from research analysts about Access Pharmaceuticals stock:
  • 1. HC Wainwright analysts commented, "for ABO-202 in Batten Disease; Reiterate Buy Stock Data 04/19/2018 Price $20.05 Exchange NASDAQ Price Target $30.00 52-Week High $22.75 52-Week Low $4.55 Enterprise Value (M) $809.2 Market Cap (M) $947 Public Market Float (M) 24.7 Shares Outstanding (M) 47.2 3 Month Avg Volume 1,230,320 Short Interest (M) 7.59 Balance Sheet Metrics Cash (M) $137.8 Total Debt (M) $0.0 Total Cash/Share $2.92 Book Value/Share $3.63 EPS Diluted Full Year – Dec 2016A 2017A 2018E 1Q (0.17) (0.13) (0.18) 2Q (0.20) (0.21) (0.19) 3Q (0.08) (0.13) (0.21) 4Q (0.18) (0.19) (0.22) FY (0.64) (0.66) (0.81) Revenue ($M) Full Year – Dec 2016A 2017A 2018E 1Q 0.2 0.2 0.4 2Q 0.2 0.2 0.4 3Q 0.2 0.2 0.4 4Q 0.3 0.2 0.4 FY 0.9 0.8 1.4 25 20 15 10 5 0 APR-17 AUG-17 DEC-17 APR-18 5 4 3 2 1 0 Vol. (mil) Price Orphan Drug Designation obtained for ABO-202 in Europe." (4/20/2018)
  • 2. According to Zacks Investment Research, "Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States. " (3/21/2018)
  • 3. Maxim Group analysts commented, "Abeona announced positive early data for ABO-101 in the first patient treated in the P1/2 trial for Sanfilippo Syndrome Type IIIB. As a reminder, this is the second gene therapy candidate targeting Sanfilippo Syndrome behind ABO-102, which has demonstrated positive data in 8 patients so far with Type IIIA disease. The difference between ABO-101 and ABO-102 is the replaced gene, same targeted pathway." (2/7/2018)

Who are some of Access Pharmaceuticals' key competitors?

Who are Access Pharmaceuticals' key executives?

Access Pharmaceuticals' management team includes the folowing people:
  • Mr. Steven H. Rouhandeh, Exec. Chairman & Principal Exec. officer (Age 61)
  • Dr. Timothy J. Miller, Pres, Chief Scientific Officer & Director (Age 46)
  • Mr. Jeffrey Blaine Davis, Chief Operating Officer (Age 55)
  • Mr. Carsten Thiel, Chief Exec. Officer (Age 54)
  • Mr. Stephen B. Thompson, Sr. VP of Fin. and Admin., Chief Accounting Officer, Sec. & Treasurer (Age 64)

Has Access Pharmaceuticals been receiving favorable news coverage?

News headlines about ABEO stock have been trending somewhat positive this week, according to Accern Sentiment. The research group scores the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Access Pharmaceuticals earned a coverage optimism score of 0.20 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 46.33 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

Who are Access Pharmaceuticals' major shareholders?

Access Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (10.22%), FMR LLC (10.22%), FMR LLC (8.35%) and FMR LLC (8.35%). View Institutional Ownership Trends for Access Pharmaceuticals.

How do I buy shares of Access Pharmaceuticals?

Shares of ABEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Access Pharmaceuticals' stock price today?

One share of ABEO stock can currently be purchased for approximately $20.00.

How big of a company is Access Pharmaceuticals?

Access Pharmaceuticals has a market capitalization of $987.04 million and generates $840,000.00 in revenue each year. The biopharmaceutical company earns $-27,310,000.00 in net income (profit) each year or ($0.66) on an earnings per share basis. Access Pharmaceuticals employs 42 workers across the globe.

How can I contact Access Pharmaceuticals?

Access Pharmaceuticals' mailing address is 3333 LEE PARKWAY SUITE 600, DALLAS TX, 75219. The biopharmaceutical company can be reached via phone at 214-665-9495 or via email at [email protected]


MarketBeat Community Rating for Access Pharmaceuticals (ABEO)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  287 (Vote Outperform)
Underperform Votes:  142 (Vote Underperform)
Total Votes:  429
MarketBeat's community ratings are surveys of what our community members think about Access Pharmaceuticals and other stocks. Vote "Outperform" if you believe ABEO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABEO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Access Pharmaceuticals (NASDAQ:ABEO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
8 Wall Street analysts have issued ratings and price targets for Access Pharmaceuticals in the last 12 months. Their average twelve-month price target is $30.4286, suggesting that the stock has a possible upside of 52.14%. The high price target for ABEO is $36.00 and the low price target for ABEO is $26.00. There are currently 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $30.4286$28.50$27.00$24.1250
Price Target Upside: 52.14% upside96.28% upside56.07% upside49.84% upside

Access Pharmaceuticals (NASDAQ:ABEO) Consensus Price Target History

Price Target History for Access Pharmaceuticals (NASDAQ:ABEO)

Access Pharmaceuticals (NASDAQ:ABEO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/20/2018HC WainwrightReiterated RatingBuy$30.00MediumView Rating Details
4/9/2018Maxim GroupSet Price TargetBuy$35.00HighView Rating Details
3/20/2018Cantor FitzgeraldSet Price TargetBuy$36.00HighView Rating Details
1/24/2018Royal Bank of CanadaReiterated RatingBuy$26.00LowView Rating Details
11/22/2017Jefferies GroupReiterated RatingBuy$28.00N/AView Rating Details
11/8/2017SunTrust BanksInitiated CoverageBuy$26.00N/AView Rating Details
10/10/2017CitigroupInitiated CoverageBuy$32.00N/AView Rating Details
5/26/2017FBR & CoReiterated RatingBuyN/AView Rating Details
2/7/2017Rodman & RenshawReiterated RatingBuy$17.00 -> $20.00N/AView Rating Details
(Data available from 4/23/2016 forward)

Earnings

Access Pharmaceuticals (NASDAQ:ABEO) Earnings History and Estimates Chart

Earnings by Quarter for Access Pharmaceuticals (NASDAQ:ABEO)

Access Pharmaceuticals (NASDAQ:ABEO) Earnings Estimates

2018 EPS Consensus Estimate: ($0.86)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.21)($0.19)($0.20)
Q2 20182($0.22)($0.20)($0.21)
Q3 20182($0.23)($0.22)($0.23)
Q4 20182($0.24)($0.21)($0.23)

Access Pharmaceuticals (NASDAQ ABEO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/21/2018        
3/16/2018Q4 2017($0.1410)($0.19)$0.24 million$0.22 millionViewN/AView Earnings Details
11/15/2017Q3 2017($0.1850)($0.13)$0.22 million$0.22 millionViewN/AView Earnings Details
8/15/2017Q2 2017($0.1420)($0.21)$0.21 million$0.22 millionViewN/AView Earnings Details
5/18/2017Q1 2017($0.15)($0.13)$0.28 million$0.19 millionViewN/AView Earnings Details
3/31/201712/31/2016($0.14)($0.19)$0.19 million$0.26 millionViewN/AView Earnings Details
11/14/2016Q316($0.19)($0.08)$0.23 million$0.18 millionViewN/AView Earnings Details
8/16/2016Q2($0.14)($0.20)$0.27 million$0.21 millionViewN/AView Earnings Details
5/16/2016Q1 2016($0.11)($0.17)$0.30 million$0.24 millionViewN/AView Earnings Details
3/30/2016Q1($0.13)($0.17)$0.22 millionViewN/AView Earnings Details
11/17/2015Q3 2015($0.11)($0.19)$0.33 million$0.29 millionViewN/AView Earnings Details
8/14/2015Q2 2015($0.10)($0.16)$0.15 million$0.28 millionViewN/AView Earnings Details
5/14/2015Q1 2015($0.10)$0.26 millionViewN/AView Earnings Details
11/14/2014Q3 2014($4.15)$0.24 millionViewN/AView Earnings Details
8/14/2014Q2 2014($3.00)$0.25 millionViewN/AView Earnings Details
5/12/2014Q1 2014($4.00)$0.21 millionViewN/AView Earnings Details
3/26/2014Q4 2013($3.50)$0.16 millionViewN/AView Earnings Details
11/14/2013Q3 2013($2.00)$0.19 millionViewN/AView Earnings Details
8/14/2013Q2 2013($5.50)$0.47 millionViewN/AView Earnings Details
5/16/2013Q1 2013($2.50)$1.22 millionViewN/AView Earnings Details
3/19/2013Q4 2012($4.00)ViewN/AView Earnings Details
11/14/2012Q3 2012($3.05)ViewN/AView Earnings Details
8/14/2012Q2 2012($4.40)ViewN/AView Earnings Details
5/15/2012Q1 2012($4.00)($2.70)ViewN/AView Earnings Details
3/23/2012Q4 2011($2.80)ViewN/AView Earnings Details
11/14/2011Q3 2011($7.50)($3.00)ViewN/AView Earnings Details
8/15/2011Q2 2011($7.85)ViewN/AView Earnings Details
5/16/2011Q1 2011($7.50)($7.15)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Access Pharmaceuticals (NASDAQ:ABEO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Access Pharmaceuticals (NASDAQ ABEO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.70%
Institutional Ownership Percentage: 62.01%
Insider Trading History for Access Pharmaceuticals (NASDAQ:ABEO)
Insider Trading History for Access Pharmaceuticals (NASDAQ:ABEO)

Access Pharmaceuticals (NASDAQ ABEO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/20/2016Todd WiderDirectorBuy5,000$5.48$27,400.0075,000View SEC Filing  
7/31/2015Mark J AhnDirectorBuy18,182$5.50$100,001.00View SEC Filing  
1/26/2015Mark J AhnDirectorBuy25,000$4.00$100,000.00View SEC Filing  
12/24/2014Steven H RouhandehDirectorBuy250,000$4.00$1,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Access Pharmaceuticals (NASDAQ ABEO) News Headlines

Source:
DateHeadline
Abeona Announces FDA Grants RMAT Designation to ABO-102 Gene Therapy in MPS IIIAAbeona Announces FDA Grants RMAT Designation to ABO-102 Gene Therapy in MPS IIIA
finance.yahoo.com - April 23 at 10:04 AM
Abeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten DiseaseAbeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease
finance.yahoo.com - April 20 at 4:09 PM
Access Pharmaceuticals (ABEO) Receives Buy Rating from HC WainwrightAccess Pharmaceuticals (ABEO) Receives Buy Rating from HC Wainwright
www.americanbankingnews.com - April 20 at 11:53 AM
Access Pharmaceuticals Inc. (ABEO) Expected to Post Quarterly Sales of $270,000.00Access Pharmaceuticals Inc. (ABEO) Expected to Post Quarterly Sales of $270,000.00
www.americanbankingnews.com - April 20 at 2:32 AM
Access Pharmaceuticals (ABEO) Stock Rating Upgraded by BidaskClubAccess Pharmaceuticals (ABEO) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - April 19 at 11:33 AM
Access Pharmaceuticals (ABEO) Lifted to "Buy" at Zacks Investment ResearchAccess Pharmaceuticals (ABEO) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 19 at 11:31 AM
Access Pharmaceuticals Inc. (ABEO) Expected to Post Earnings of -$0.19 Per ShareAccess Pharmaceuticals Inc. (ABEO) Expected to Post Earnings of -$0.19 Per Share
www.americanbankingnews.com - April 18 at 5:18 PM
Access Pharmaceuticals (ABEO) Stock Rating Lowered by BidaskClubAccess Pharmaceuticals (ABEO) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 15 at 2:21 PM
Access Pharmaceuticals (ABEO) Downgraded by BidaskClub to HoldAccess Pharmaceuticals (ABEO) Downgraded by BidaskClub to Hold
www.americanbankingnews.com - April 14 at 1:31 PM
Access Pharmaceuticals (ABEO) Upgraded at BidaskClubAccess Pharmaceuticals (ABEO) Upgraded at BidaskClub
www.americanbankingnews.com - April 14 at 7:21 AM
When Will Abeona Therapeutics Inc (NASDAQ:ABEO) Breakeven?When Will Abeona Therapeutics Inc (NASDAQ:ABEO) Breakeven?
finance.yahoo.com - April 13 at 10:18 AM
Abeona Therapeutics (ABEO) PT Set at $30.00 by HC WainwrightAbeona Therapeutics (ABEO) PT Set at $30.00 by HC Wainwright
www.americanbankingnews.com - April 12 at 11:17 AM
Why Abeona Therapeutics (ABEO) Could Be Positioned for a SlumpWhy Abeona Therapeutics (ABEO) Could Be Positioned for a Slump
finance.yahoo.com - April 10 at 10:17 AM
Today’s Research Reports on Trending Tickers: Abeona Therapeutics and Spark TherapeuticsToday’s Research Reports on Trending Tickers: Abeona Therapeutics and Spark Therapeutics
finance.yahoo.com - April 10 at 10:17 AM
Abeona Therapeutics (ABEO) Given a $35.00 Price Target by Maxim Group AnalystsAbeona Therapeutics (ABEO) Given a $35.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - April 9 at 1:19 PM
Abeona Therapeutics (ABEO) Now Covered by Analysts at CitigroupAbeona Therapeutics (ABEO) Now Covered by Analysts at Citigroup
www.americanbankingnews.com - April 7 at 6:36 PM
Abeona Therapeutics (ABEO) Rating Reiterated by HC WainwrightAbeona Therapeutics (ABEO) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - April 7 at 12:31 PM
ValuEngine Upgrades Abeona Therapeutics (ABEO) to HoldValuEngine Upgrades Abeona Therapeutics (ABEO) to Hold
www.americanbankingnews.com - April 3 at 8:13 PM
Zacks: Analysts Anticipate Abeona Therapeutics Inc (ABEO) Will Post Quarterly Sales of $270,000.00Zacks: Analysts Anticipate Abeona Therapeutics Inc (ABEO) Will Post Quarterly Sales of $270,000.00
www.americanbankingnews.com - April 3 at 2:44 AM
BRIEF-Abeona Therapeutics Appoints Carsten Thiel, Ph.D., As Chief Executive OfficerBRIEF-Abeona Therapeutics Appoints Carsten Thiel, Ph.D., As Chief Executive Officer
www.reuters.com - April 2 at 4:07 PM
New chief at AbeonaNew chief at Abeona
seekingalpha.com - April 2 at 4:07 PM
BRIEF-Abeona Therapeutics Appoints Carsten Thiel As Chief Executive OfficerBRIEF-Abeona Therapeutics Appoints Carsten Thiel As Chief Executive Officer
www.reuters.com - April 2 at 10:35 AM
Abeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive OfficerAbeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive Officer
finance.yahoo.com - April 2 at 10:35 AM
Abeona Therapeutics (ABEO) Given a $30.00 Price Target by HC Wainwright AnalystsAbeona Therapeutics (ABEO) Given a $30.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - April 2 at 9:34 AM
-$0.19 EPS Expected for Abeona Therapeutics Inc (ABEO) This Quarter-$0.19 EPS Expected for Abeona Therapeutics Inc (ABEO) This Quarter
www.americanbankingnews.com - April 1 at 3:17 PM
Abeona Therapeutics Inc (ABEO) Receives Consensus Recommendation of "Buy" from AnalystsAbeona Therapeutics Inc (ABEO) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 1 at 1:30 PM
HC Wainwright Analysts Give Abeona Therapeutics (ABEO) a $30.00 Price TargetHC Wainwright Analysts Give Abeona Therapeutics (ABEO) a $30.00 Price Target
www.americanbankingnews.com - March 30 at 3:58 PM
SunTrust Banks Weighs in on Abeona Therapeutics Incs Q1 2018 Earnings (ABEO)SunTrust Banks Weighs in on Abeona Therapeutics Inc's Q1 2018 Earnings (ABEO)
www.americanbankingnews.com - March 30 at 6:50 AM
Abeona Therapeutics (ABEO) CEO Dr. Timothy J. Miller on Q4 2017 Results - Earnings Call TranscriptAbeona Therapeutics' (ABEO) CEO Dr. Timothy J. Miller on Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - March 28 at 3:58 PM
Edited Transcript of ABEO earnings conference call or presentation 27-Mar-18 2:00pm GMTEdited Transcript of ABEO earnings conference call or presentation 27-Mar-18 2:00pm GMT
finance.yahoo.com - March 28 at 10:02 AM
Krystal Bios progress in DEB pressures Abeona, down 5%Krystal Bio's progress in DEB pressures Abeona, down 5%
seekingalpha.com - March 27 at 4:11 PM
Abeona Therapeutics, Inc. to Host Earnings CallAbeona Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - March 27 at 10:12 AM
Abeona Therapeutics (ABEO) Lowered to "Sell" at BidaskClubAbeona Therapeutics (ABEO) Lowered to "Sell" at BidaskClub
www.americanbankingnews.com - March 27 at 12:06 AM
JFs Core Biotech Buys #8: Taking Advantage Of Volatility And Initiating A Position In DynavaxJF's Core Biotech Buys #8: Taking Advantage Of Volatility And Initiating A Position In Dynavax
seekingalpha.com - March 26 at 4:08 PM
HC Wainwright Reiterates Buy Rating for Abeona Therapeutics (ABEO)HC Wainwright Reiterates Buy Rating for Abeona Therapeutics (ABEO)
www.americanbankingnews.com - March 25 at 10:56 PM
Abeona Therapeutics (ABEO) Rating Increased to Hold at ValuEngineAbeona Therapeutics (ABEO) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - March 25 at 9:48 PM
Critical Review: Abeona Therapeutics (ABEO) and Kala Pharmaceuticals (KALA)Critical Review: Abeona Therapeutics (ABEO) and Kala Pharmaceuticals (KALA)
www.americanbankingnews.com - March 24 at 11:20 PM
Abeona Therapeutics (ABEO) Given a $36.00 Price Target at Cantor FitzgeraldAbeona Therapeutics (ABEO) Given a $36.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - March 21 at 7:48 PM
Abeona Therapeutics (ABEO) Downgraded by Zacks Investment Research to SellAbeona Therapeutics (ABEO) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - March 21 at 4:40 PM
Brokers Offer Predictions for Abeona Therapeutics Incs Q1 2018 Earnings (ABEO)Brokers Offer Predictions for Abeona Therapeutics Inc's Q1 2018 Earnings (ABEO)
www.americanbankingnews.com - March 21 at 7:20 AM
Abeona Therapeutics Inc (ABEO) Expected to Earn FY2022 Earnings of $3.11 Per ShareAbeona Therapeutics Inc (ABEO) Expected to Earn FY2022 Earnings of $3.11 Per Share
www.americanbankingnews.com - March 20 at 4:54 PM
15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies
finance.yahoo.com - March 20 at 4:11 PM
Abeona Therapeutics (ABEO) PT Set at $35.00 by Maxim GroupAbeona Therapeutics (ABEO) PT Set at $35.00 by Maxim Group
www.americanbankingnews.com - March 19 at 5:02 PM
Abeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business Highlights - GlobeNewswire (press release)Abeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business Highlights - GlobeNewswire (press release)
globenewswire.com - March 18 at 4:10 PM
Abeona Therapeutics Inc: Abeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business HighlightsAbeona Therapeutics Inc: Abeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business Highlights
www.finanznachrichten.de - March 17 at 10:52 AM
Abeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business HighlightsAbeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business Highlights
finance.yahoo.com - March 17 at 10:52 AM
Abeona Therapeutics (ABEO) Posts  Earnings Results, Misses Estimates By $0.05 EPSAbeona Therapeutics (ABEO) Posts Earnings Results, Misses Estimates By $0.05 EPS
www.americanbankingnews.com - March 16 at 9:08 PM
Abeona Therapeutics (ABEO) Reports FDA Rare Pediatric Disease Designation for ABO-202Abeona Therapeutics (ABEO) Reports FDA Rare Pediatric Disease Designation for ABO-202
www.streetinsider.com - March 16 at 10:59 AM
Abeona Therapeutics Receives FDA Rare Pediatric Disease Designation for ABO-202 Gene Therapy Program in CLN1 ... - GlobeNewswire (press release)Abeona Therapeutics Receives FDA Rare Pediatric Disease Designation for ABO-202 Gene Therapy Program in CLN1 ... - GlobeNewswire (press release)
globenewswire.com - March 15 at 4:08 PM
Abeona Therapeutics Receives FDA Rare Pediatric Disease Designation for ABO-202 Gene Therapy Program in CLN1 DiseaseAbeona Therapeutics Receives FDA Rare Pediatric Disease Designation for ABO-202 Gene Therapy Program in CLN1 Disease
finance.yahoo.com - March 15 at 10:53 AM

SEC Filings

Access Pharmaceuticals (NASDAQ:ABEO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Access Pharmaceuticals (NASDAQ:ABEO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Access Pharmaceuticals (NASDAQ ABEO) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.